Allogene Therapeutics, Inc. Share Price Today: Live Updates & Key Insights
Allogene Therapeutics, Inc. share price today is $1.75, up -4.4%. The stock opened at $1.82 against the previous close of $1.82, with an intraday high of $1.82 and low of $1.74.
Allogene Therapeutics, Inc. Share Price Chart
Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. Share Price Performance
Allogene Therapeutics, Inc. Institutional Holdings
Allogene Therapeutics, Inc. Market Status
Allogene Therapeutics, Inc. Fundamentals
Market Cap 628.18 M
PB Ratio 2.3021
PE Ratio 0.0
Enterprise Value 447.73 M
Total Assets 415.91 M
Volume 4874170
Allogene Therapeutics, Inc. Company Financials
About Allogene Therapeutics, Inc. & investment objective
Company Information Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Organisation Biotechnology
Employees 150
Industry Biotechnology
CEO Dr. Zachary J. Roberts M.D., Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Allogene Therapeutics, Inc. FAQs
What is the share price of Allogene Therapeutics, Inc. today?
The current share price of Allogene Therapeutics, Inc. is $1.75.
Can I buy Allogene Therapeutics, Inc. shares in India?
Yes, Indian investors can buy Allogene Therapeutics, Inc. shares by opening an international trading and demat account with Motilal Oswal.
How to buy Allogene Therapeutics, Inc. shares in India?
You can easily invest in Allogene Therapeutics, Inc. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Allogene Therapeutics, Inc. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Allogene Therapeutics, Inc..
Can I buy fractional shares of Allogene Therapeutics, Inc.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Allogene Therapeutics, Inc.?
Allogene Therapeutics, Inc. has a market cap of $628.18 M.
In which sector does Allogene Therapeutics, Inc. belong?
Allogene Therapeutics, Inc. operates in the Biotechnology sector.
What documents are required to invest in Allogene Therapeutics, Inc. stocks?
To invest, you typically need:
What is the PE and PB ratio of Allogene Therapeutics, Inc.?
The PE ratio of Allogene Therapeutics, Inc. is N/A and the PB ratio is 2.30.